In an adult male being evaluated for prostate cancer, what is the role of transrectal prostate ultrasound?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Role of Transrectal Ultrasound in Prostate Cancer Evaluation

Transrectal ultrasound (TRUS) alone is not recommended as a primary diagnostic tool for prostate cancer detection, as PSA is a better predictor of cancer than either digital rectal examination (DRE) or TRUS. 1

Primary Diagnostic Role

  • TRUS has limited capacity to identify prostate cancer due to poor specificity and variability in the ultrasonic appearance of tumors, particularly for early-stage, clinically impalpable cancers that are ultrasonically indistinguishable from normal prostate tissue. 2

  • PSA is superior to TRUS as an independent predictor of prostate cancer, making TRUS inadequate as a standalone screening or diagnostic modality. 1

Current Clinical Applications

Biopsy Guidance (Primary Role)

The principal role of TRUS in modern practice is to facilitate systematic prostate biopsy, not to directly visualize cancer. 2 Specifically:

  • TRUS guides both transrectal and transperineal biopsy approaches with similar cancer detection rates, though the transperineal approach shows lower infection rates while transrectal approaches have lower urinary retention rates. 3

  • TRUS enables accurate sampling of the prostate gland through systematic biopsy protocols rather than lesion-directed biopsies, given that most prostate cancers detected today have no specific sonographic findings. 4, 2

Volume Measurement for Risk Stratification

  • TRUS provides prostate volume measurements that are essential for calculating PSA density (PSA-D = serum PSA ÷ prostate volume), which is one of the strongest predictors in risk calculators using a cut-off of 0.15 ng/ml/cc. 1

  • PSA-D helps predict clinically significant prostate cancer (csPCa), especially in smaller prostates, and may allow men to avoid unnecessary biopsies. 1

Integration with Modern Imaging

MRI-TRUS Fusion

Multiparametric MRI (mpMRI) has largely superseded TRUS for cancer detection, with pooled sensitivity of 0.91-0.95 for clinically significant cancers. 1 However:

  • TRUS can be combined with mpMRI to perform fusion biopsies targeting specific MRI-identified lesions, improving diagnostic accuracy. 3, 5

  • MRI-based biopsy indication leads to lower overall biopsy rates, fewer insignificant cancer diagnoses, and more clinically significant cancer detection compared to TRUS-guided systematic biopsy alone. 1

Risk-Adapted Approach

Combining PSA-D (measured via TRUS) with PI-RADS scores creates a risk-adapted matrix that guides biopsy decisions more effectively than either modality alone. 1

Common Pitfalls to Avoid

  • Do not rely on TRUS to "see" prostate cancer – most cancers are isoechoic and invisible on standard ultrasound. 4, 2

  • Do not use TRUS as a screening tool – it should only be employed when biopsy is already indicated based on PSA, DRE, or MRI findings. 1

  • Do not perform lesion-directed biopsies based solely on TRUS findings – systematic sampling protocols are superior given the poor specificity of ultrasound for cancer detection. 2

Emerging Technologies

  • Micro-ultrasound generates higher resolution images than traditional TRUS and has shown effectiveness in diagnosing prostate cancer, potentially becoming a future standard of care. 3

  • High-intensity focused ultrasound (HIFU) focal therapy administered via TRUS offers safe short-term oncological control for localized disease with low morbidity. 3

Staging Limitations

TRUS plays no role in staging prostate cancer. For high-risk disease, guidelines recommend:

  • Bone scan plus pelvic mpMRI or CT scan for staging evaluation. 6
  • mpMRI is preferred for local tumor staging over TRUS or CT. 6
  • Molecular imaging (PSMA PET) may be considered for high-risk patients with negative conventional imaging. 6

References

4
Research

Transrectal ultrasound and biopsy in the early diagnosis of prostate cancer.

Cancer control : journal of the Moffitt Cancer Center, 2001

5
Research

Role of transrectal ultrasonography in prostate cancer.

Radiologic clinics of North America, 2012

Related Questions

How should a patient with prostate cancer metastasis to the colon be evaluated and managed?
What is the appropriate hormonal therapy regimen for prostate cancer?
What is the Prostate Imaging‑Reporting and Data System (PI‑RADS) scoring system for prostate cancer magnetic resonance imaging?
What are the causes of proximal muscle weakness in a man with prostate cancer?
In a 59-year-old man with a long-standing indwelling urinary catheter awaiting definitive surgery for prostate cancer who now has pain at the tip of the penis, what are the differential diagnoses and appropriate management plan?
In a woman with a hemorrhagic ovarian cyst measuring 4.3 × 3.9 cm on CT and severe pelvic pain (8/10), what is the recommended treatment?
What are the likely causes of jaw pain radiating to the ear, throat, and side of the face, and how should it be evaluated and managed?
In a hypertensive patient with hyponatremia (serum sodium 130 mmol/L), can amlodipine cause hyponatremia?
What does a urinalysis showing absent white‑blood cells and red‑blood cells, normal non‑renal epithelial cells, absent renal epithelial cells, no casts, and the presence of calcium‑oxalate crystals, yeast, and Trichomonas indicate and how should it be managed?
How many milliliters of Saxenda (liraglutide) are needed for a 90‑day course if the patient takes the full 3 mL (6 mg/mL) daily?
In an older adult with dementia‑related agitation who is already taking buspirone for anxiety, should I discontinue buspirone when initiating low‑dose quetiapine (Seroquel) for agitation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.